Vitamin D3 + K2

The two vitamins split one job between them: D3 brings calcium into the body and K2 routes it to the right place, which is why pairing them makes physiological sense once you're on a real dose of D3, above 1,000 IU. D3 pulls a lot more calcium in through your gut. K2 is what tells that calcium where to go: it switches on osteocalcin (the protein that locks calcium into bone) and Matrix Gla Protein (the one that keeps calcium out of your arteries). Without enough K2, the extra calcium D3 brings in has no clear destination, and population data suggests this may feed arterial calcification in people who supplement D3 but run low on K2. A combined product just saves you from buying two separate bottles.

First, the part that is settled: D3 on its own. Large reviews confirm it reduces all-cause mortality, and 35-42% of American adults are deficient - so there is a real chance you are low, especially if you spend most of your day indoors. For bone health, immune function, and mortality, the D3 evidence is among the most solid in the whole supplement world.

K2 is the piece that adds the artery-protection layer. One 10-year study found that high K2 intake tracked with a 52% lower risk of severe artery calcification and a 57% lower risk of dying from coronary heart disease. K1 (the form in leafy greens) showed nothing like this. That is exactly why K2 earns its place once D3 has your calcium absorption running higher.

So the practical case is simple: if you are taking any meaningful dose of vitamin D3 (above 1,000 IU), adding K2 is low-risk, low-cost, and biologically sensible. A combined product is just more convenient than two bottles. Both are fat-soluble, so take them with food that has some fat in it.

Now the detail most labels gloss over - which K2 you are actually getting. There are two forms, MK-7 and MK-4, and they behave very differently. MK-7 is the right one for a once-a-day pill: its 68-72 hour half-life means a single daily dose keeps active levels up around the clock. MK-4 clears fast - a plasma half-life of only 60-90 minutes, and at a 420mcg oral dose it was completely undetectable in serum at every time point measured. Even at 15mg (15,000mcg), MK-4 peaks in 2-6 hours and is swept out the same day. To show clinical effects it takes pharmaceutical doses of 45,000mcg (45mg) three times daily. So the small MK-4 amounts you see on some labels (5-15mcg) are essentially doing nothing. MK-7 is different: with that 68-72 hour half-life, after 7 days of consecutive daily dosing serum MK-7 climbs to 7-8 fold above baseline, while MK-4 never accumulates that way. The reason is how each one travels: MK-4 rides chylomicrons and gets cleared by the liver on the first pass, while MK-7 gets packed into LDL and HDL, which carry it out to the tissues that matter - the bone matrix and the vascular smooth muscle cells where osteocalcin and MGP get activated.

Dose matters too, and one trial maps it out cleanly. A randomized double-blind placebo-controlled dose-response RCT (Dalmeijer et al. 2012, PMID: 23062766, n=60, aged 40-65, 12 weeks) set thresholds for MK-7: 100mcg/day covers a nutritional baseline; 180mcg/day cut the ucOC/cOC osteocalcin ratio by 60% and the calcification marker dp-ucMGP by 31%; 360mcg/day cut the osteocalcin ratio by 74% and dp-ucMGP by 46%. Those two markers track different things - the osteocalcin ratio reflects bone metabolism, dp-ucMGP reflects how well vascular calcification is being held back. The takeaway for shopping: a product with only 45mcg K2 gives you baseline coverage but stays under the threshold the cardiovascular research actually used.

The strongest argument for combining D3 with K2 comes from where D3 alone falls short. The Bjelakovic 2014 Cochrane review (56 RCTs, 95,286 participants) found D3 reduced all-cause mortality (RR 0.97, 95% CI 0.94-0.99) but did nothing for cardiovascular mortality - the entire mortality benefit came from fewer cancer deaths. The 2017 ViDA trial (Scragg et al., JAMA Cardiology) confirmed it: D3 by itself had zero effect on cardiovascular disease, heart failure, or heart attack. The explanation is that calcium paradox again - D3 turns up calcium absorption (via TRPV6 channels and calbindin) but cannot steer where the calcium ends up. K2 activates Matrix Gla Protein, the body's most potent built-in brake on vascular calcification, to keep calcium from settling in arteries.